Canopy Growth Corporation - Common Shares (CGC)

The cannabis industry is still finding its footing, but Tilray just posted record revenue with its beverage business turning profitable. Canopy is narrowing losses and targeting positive EBITDA by fiscal year-end.

Canopy pursues a lean U.S.-focused strategy while Tilray has diversified into beverages, but their diverging paths and financial profiles reveal starkly different risk-reward profiles for 2026.

The company is still burning through cash, and its outlook doesn't look all that great.

Improving fundamentals are making Canopy harder to ignore.

Canopy Growth's stock has continued to fall, prompting the company to proactively seek to retain access to capital markets.

Two long-standing issues continue to weigh on this cannabis stock.

Revenue is growing, but the cannabis company still has a lot to prove to investors.

Canopy Growth benefited from growth across all its divisions in the first quarter of fiscal 2027, but does that make it a worthwhile investment?

The Canadian cannabis companies are both seeing strong growth, but one is a better buy right now.

After a huge gold rush, the marijuana sector stumbled, and now consolidation is gaining momentum.

Cannabis consolidation appears to be accelerating.

Revenue grew 13% as MTL integration and Polish market strength drove results.

Curaleaf is attempting to acquire Canopy Growth's rival, Aurora Cannabis, and there could be more consolidation to come in the industry.

Canopy Growth (NASDAQ:CGC) is positioning itself for further expansion in medical cannabis, European markets and Canadian recreational cannabis after restructuring operations, reducing costs and acquiring MTL Cannabis, President and CEO Luc Mongeau said during a Canaccord Genuity presentation. Mong

The turnaround is becoming more believable.

Canopy Growth is a marijuana stock, but U.S. regulations aren't the main driver of its business.

Canopy Growth (NASDAQ:CGC) reported first-quarter fiscal 2027 net revenue of C$81.2 million, up 13% from the prior-year period, as the company recorded year-over-year growth across its cannabis and Storz & Bickel businesses. Chief Executive Officer Luc Mongeau said the quarter marked the first

The next key catalyst for this cannabis stock lies in the hands of a U.S. Federal Government agency.

The president directed federal authorities to reschedule medical marijuana.

A lower stock price doesn't eliminate investment risk.

Shares of the cannabis company have fallen below the $1 mark again.

Be careful before bucking the bearish trend.

Canopy Growth's medical marijuana division had a great quarter, but the rest of the business wasn't so lucky.

Canopy Growth is a much riskier stock than it was five years ago.

Canopy Growth (NASDAQ:CGC) reported higher fiscal fourth-quarter revenue and said it entered fiscal 2027 with a stronger balance sheet following a year of restructuring, cost cuts and the acquisition of MTL Cannabis. On the company’s earnings call, Chief Executive Officer Luc Mongeau described fisc